Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 16/20 | 0.55 |
| ▸ | RAB9A | P51151 | 13/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 10/20 | 0.55 |
| ▸ | MITF | O75030 | 7/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.54 |
| ▸ | LMNA | P02545 | 10/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.54 |
| ▸ | NPC1 | O15118 | 10/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 9/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7806721 | 0.88 | HTT (0.46) | HTTRAB9ANPSR1MITFPKM | |
| SCHEMBL4194133 | 0.83 | HTT (0.43) | HTTRAB9ANPSR1MITFPKM | |
| SCHEMBL9372672 | 0.81 | HTT (0.60) | HTTRAB9ANPSR1MITFPKM | |
| SCHEMBL9529443 | 0.79 | HTT (0.59) | HTTRAB9ANPSR1MITFPKM | |
| SCHEMBL15674013 | 0.79 | HTT (0.59) | HTTRAB9ANPSR1MITFPKM | |
| SCHEMBL9372329 | 0.78 | HTT (0.57) | HTTRAB9ANPSR1MITFPKM | |
| SCHEMBL14574536 | 0.76 | HTT (0.56) | HTTRAB9ANPSR1MITFPKM | |
| SCHEMBL15674046 | 0.76 | HTT (0.58) | HTTRAB9ANPSR1MITFPKM | |
| SCHEMBL980058 | 0.76 | HTT (0.60) | HTTRAB9ANPSR1MITFPKM | |
| SCHEMBL4184566 | 0.75 | PTGS2 (0.40) | HTTRAB9ANPSR1MITFPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180305345-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ONCOLYTIC VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2018-10-25 | — | — | US | claimed |
| EP-3250550-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | Ottawa Hospital Research Institute (CA) | 2017-12-06 | — | — | EP | claimed |
| WO-2016119052-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ONCOLYTIC VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-08-04 | — | — | WO | claimed |
| WO-2016119051-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-08-04 | — | — | WO | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-12195451-B2 | Compositions and methods for viral sensitization | Ottawa Hospital Research Institute and University of Ottawa (CA) | 2025-01-14 | — | — | US | disclosed |
| US-20240360115-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2024-10-31 | — | — | US | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4356971-A2 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| EP-0201765-B1 | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1991-09-18 | — | — | EP | disclosed |
| US-4892947-A | 3(2H)Pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-01-09 | — | — | US | disclosed |
| EP-0201765-A2 | 3(2H)Pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195451-B2 | Compositions and methods for viral sensitization | CD4, CD74, HLA-DRB1 | HTT 3425/4885RAB9A 2894/4885NPSR1 2878/4885 |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HTT 2496/4885RAB9A 2904/4885NPSR1 1473/4885 |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | HTT 4802/4885RAB9A 4413/4885NPSR1 1515/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HTT 2496/4885RAB9A 2904/4885NPSR1 1473/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HTT 2496/4885RAB9A 2904/4885NPSR1 1473/4885 |
| US-20240360115-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | CD4, CD74, HAVCR2 | HTT 1815/4885RAB9A 3469/4885NPSR1 2700/4885 |
| US-20180305345-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ONCOLYTIC VIRUS EFFICACY | TP53, HAVCR2, TSG101 | HTT 1861/4885RAB9A 1623/4885NPSR1 4367/4885 |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | HTT 4802/4885RAB9A 4413/4885NPSR1 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.